



Senno Therapeutics has been selected for the 10th AMED “Strengthening Program for Pharmaceutical Startup Ecosystem”

January 22th, 2026

We are pleased to announce that Senno Therapeutics has been selected for the 10th AMED Strengthening Program for Pharmaceutical Startup Ecosystem.

The “Strengthening Program for Pharmaceutical Startup Ecosystem” is a support program implemented by the Japan Agency for Medical Research and Development (AMED).

The program registers venture capital (VC) firms that provide commercialization support for drug discovery and offers subsidies for pharmaceutical R&D to startups funded by those registered VCs.

This support will further accelerate our development of regenerative medicine for liver diseases using human iPSC-derived hepatoblasts, enabling us to advance process development and non-clinical studies toward clinical application.

Detail of this program: <https://www.amed.go.jp/en/program/list/19/02/005.html>

About Senno Therapeutics (<https://sennotx.com>)

Senno Therapeutics is a biotech company dedicated to developing novel therapies for fatal liver failure using human iPS cell-derived liver progenitor cells and liver organoid technologies. Senno was founded in 2024 based on iPS cell manipulation technologies developed by Professor Hideki Taniguchi at the Institute of Medical Science, the University of Tokyo.

We aim to deliver innovative cell therapies that offer patients with liver failure a lifesaving treatment option and alleviate complications from the critical shortage of donor organs.